MAINZ BIOMED NV (QUCY) Fundamental Analysis & Valuation

NASDAQ:QUCY • NL0015000LC2

Current stock price

0.5076 USD
0 (-0.45%)
At close:
0.482 USD
-0.03 (-5.04%)
After Hours:

This QUCY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. QUCY Profitability Analysis

1.1 Basic Checks

  • QUCY had negative earnings in the past year.
  • QUCY had a negative operating cash flow in the past year.
  • In the past 5 years QUCY always reported negative net income.
  • In the past 5 years QUCY always reported negative operating cash flow.
QUCY Yearly Net Income VS EBIT VS OCF VS FCFQUCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -220.85%, QUCY is doing worse than 89.53% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -858.34%, QUCY is doing worse than 80.23% of the companies in the same industry.
Industry RankSector Rank
ROA -220.85%
ROE -858.34%
ROIC N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
QUCY Yearly ROA, ROE, ROICQUCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

  • QUCY's Gross Margin of 64.31% is fine compared to the rest of the industry. QUCY outperforms 77.91% of its industry peers.
  • In the last couple of years the Gross Margin of QUCY has grown nicely.
  • The Profit Margin and Operating Margin are not available for QUCY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
QUCY Yearly Profit, Operating, Gross MarginsQUCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. QUCY Health Analysis

2.1 Basic Checks

  • QUCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for QUCY has been increased compared to 1 year ago.
  • QUCY has more shares outstanding than it did 5 years ago.
  • QUCY has a better debt/assets ratio than last year.
QUCY Yearly Shares OutstandingQUCY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
QUCY Yearly Total Debt VS Total AssetsQUCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • QUCY has an Altman-Z score of -16.51. This is a bad value and indicates that QUCY is not financially healthy and even has some risk of bankruptcy.
  • QUCY has a Altman-Z score of -16.51. This is amonst the worse of the industry: QUCY underperforms 81.59% of its industry peers.
  • A Debt/Equity ratio of 0.44 indicates that QUCY is not too dependend on debt financing.
  • QUCY has a worse Debt to Equity ratio (0.44) than 71.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -16.51
ROIC/WACCN/A
WACC6.25%
QUCY Yearly LT Debt VS Equity VS FCFQUCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 0.52 indicates that QUCY may have some problems paying its short term obligations.
  • With a Current ratio value of 0.52, QUCY is not doing good in the industry: 92.05% of the companies in the same industry are doing better.
  • QUCY has a Quick Ratio of 0.52. This is a bad value and indicates that QUCY is not financially healthy enough and could expect problems in meeting its short term obligations.
  • QUCY's Quick ratio of 0.43 is on the low side compared to the rest of the industry. QUCY is outperformed by 92.44% of its industry peers.
Industry RankSector Rank
Current Ratio 0.52
Quick Ratio 0.43
QUCY Yearly Current Assets VS Current LiabilitesQUCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. QUCY Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 65.47% over the past year.
  • QUCY shows a decrease in Revenue. In the last year, the revenue decreased by -0.17%.
  • The Revenue has been growing by 26.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.55%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%-44.95%

3.2 Future

  • Based on estimates for the next years, QUCY will show a very strong growth in Earnings Per Share. The EPS will grow by 24.17% on average per year.
  • Based on estimates for the next years, QUCY will show a very strong growth in Revenue. The Revenue will grow by 133.71% on average per year.
EPS Next Y83.39%
EPS Next 2Y38.62%
EPS Next 3Y24.17%
EPS Next 5YN/A
Revenue Next Year-17.68%
Revenue Next 2Y-7.02%
Revenue Next 3Y32.9%
Revenue Next 5Y133.71%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
QUCY Yearly Revenue VS EstimatesQUCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
QUCY Yearly EPS VS EstimatesQUCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

1

4. QUCY Valuation Analysis

4.1 Price/Earnings Ratio

  • QUCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year QUCY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QUCY Price Earnings VS Forward Price EarningsQUCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QUCY Per share dataQUCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • QUCY's earnings are expected to grow with 24.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y24.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. QUCY Dividend Analysis

5.1 Amount

  • No dividends for QUCY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

QUCY Fundamentals: All Metrics, Ratios and Statistics

MAINZ BIOMED NV

NASDAQ:QUCY (4/24/2026, 8:03:59 PM)

After market: 0.482 -0.03 (-5.04%)

0.5076

0 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)N/A
Inst Owners9.45%
Inst Owner Change0%
Ins Owners12.6%
Ins Owner ChangeN/A
Market Cap6.36M
Revenue(TTM)894.00K
Net Income(TTM)-21.65M
Analysts82.86
Price TargetN/A
Short Float %2.51%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.11
P/FCF N/A
P/OCF N/A
P/B 2.52
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.36
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.07
BVpS0.2
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -220.85%
ROE -858.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.31%
FCFM N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.98%
Cap/Sales 31.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.52
Quick Ratio 0.43
Altman-Z -16.51
F-Score5
WACC6.25%
ROIC/WACCN/A
Cap/Depr(3y)139.31%
Cap/Depr(5y)92.63%
Cap/Sales(3y)121.7%
Cap/Sales(5y)74.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.55%
EPS Next Y83.39%
EPS Next 2Y38.62%
EPS Next 3Y24.17%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%-44.95%
Revenue Next Year-17.68%
Revenue Next 2Y-7.02%
Revenue Next 3Y32.9%
Revenue Next 5Y133.71%
EBIT growth 1Y30.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.1%
OCF growth 3YN/A
OCF growth 5YN/A

MAINZ BIOMED NV / QUCY Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MAINZ BIOMED NV?

ChartMill assigns a fundamental rating of 2 / 10 to QUCY.


What is the valuation status for QUCY stock?

ChartMill assigns a valuation rating of 1 / 10 to MAINZ BIOMED NV (QUCY). This can be considered as Overvalued.


How profitable is MAINZ BIOMED NV (QUCY) stock?

MAINZ BIOMED NV (QUCY) has a profitability rating of 1 / 10.


How financially healthy is MAINZ BIOMED NV?

The financial health rating of MAINZ BIOMED NV (QUCY) is 1 / 10.


What is the expected EPS growth for MAINZ BIOMED NV (QUCY) stock?

The Earnings per Share (EPS) of MAINZ BIOMED NV (QUCY) is expected to grow by 83.39% in the next year.